All the Drug Class Drugs
Colony Stimulating Factor, Immunostimulants. Pegfilgrastim 6 mg. Pre-filled syringe 1 x 6 mg/0.6ml. One 6 mg dose for ea. chemother. cycle S.C. inject. at least 24 hours after cytotox. chemother.
Reduct. durat. neutropen., incidence of febrile neutropen. in pts. treated with cytotox. chemother. given in intervals of 14 days or more for malignancy (with the except. of chron. myeloid leukem. and myelodysplast. synds.). See lit.
C/I: Hyperens.
Colony Stimulating Factor. Lipegfilgrastim 6 mg / 0.6 ml. PREFILLED SYRINGE (sol. for inj.): 1 × 0.6
ml. One 6 mg dose of (a single pref.
syr.) for each chemoth. cycle, given approx. 24 hrs. after cytotoxic
chemoth.
Reduct. in the durat. of neutropenia and
the incidence of febrile neutropenia in
adult pts. treated with cytotoxic
chemother. for malignan. (with the
except. of chron. myeloid leukaemia and
myelodysplast. syndr.)
C/I: Hypersens.
Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml. PREFILL SYRINGE (ready-to-use) 1 x 6
mg/0.06 ml. One 6 mg dose for ea.
chemother. cycle S.C. inject. approx.
24 hrs follow. cytotox. chemother.
Reduct. durat. neutropen., incidence of
febrile neutropen. in pts. treated with cytotox. chemother. for malignancy (with
the except. of chron. myeloid leukem. and
myelodysplast. synds.)
C/I: Hyperens.
Colony Stimulating Factor. Filgrastim 30 MU/ml (0.3 mg/ml), 30 MU/0.5 ml (0.6 mg/ml), 48 MU/0.5 ml (0.96 mg/ml). VIALS (sol. for inj.): 5×30 MU (0.3 mg/ml).
PREF. SYR. (sol. for inj.): 5×30 MU (0.6 mg/ml)
1, 5×48 MU (0.96 mg/ml). Dosage ajust. individ.
accord. ptt. med. condition.
Reduct. in the durat. of neutropenia and
incid. of febrile neutropenia in pts.
treated with establ. cytotoxic
chemother. for malign. (with the except.
of chron. myeloid leukaemia and
myelodysplastic syndr.) and reduct.
in the durat. of neutropenia in pts.
undergoing myeloablative ther. followed
by bone marrow transplant., considered
to be at incr. risk of prolong. sev.
neutropenia. The safety and effic. of
Filgrastim are similar in adults and child.
receiving cytotoxic chemother. Indic. for
the mobilization of peripheral blood
progenitor cells (PBPCs). In pts., children/
adults, with severe congen., cyclic or
idiopathic neutropenia with an ANC of
≤0.5 ×10^9/l, and a hist. of sev. or
recurr. infetc., long-term admin. of this
drug is indic. to incr. neutrophil
counts and to red. the incid. and
durat. of infect.-related events.
For the tmt. of persistent neutropenia (ANC less than or equal to 1.0 × 109/l) in pts with adv. HIV infect., to red. the risk of bact. infect. when other options to manage neutropenia are inappr.
C/I: Hypersens
Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml. PREFILL. SYR.: 1 x 6 mg / 0.6 mL. One 6 mg for ea. chemother. cycle, S.C. inject. at least 24 hrs. after cytotox. chemother. See lit.
Reduct. durat. neutropen., incidence of febrile neutropen. in pts. treat. with cytotox. chemother.at interval. of 14 dys. or more, for malignan. (with the exception of chronic myeloid leukemia and myelodysplastic synd.).
C/I: Hypersens.
Colony Stimulating Factor. Filgrastim 300 mcg/0.5 ml, 480mcg/0.5ml. PREF.SYR. (sol. for inj. or infus.):1,3,5,10×. Dosage ajust. individ. accord. pt. med. condition.
Indicated for the reduct. in the duration of neutropen. and the incidence of febrile neutropen. in pts. treated with established cytotoxic chemother. for malignan. (with the exception of chronic myeloid leukaem. and myelodysplastic syndr.) and for the reduc. in the duration of neutropen. in pts. underg. myeloablative therapy followed by bone marrow transplantat. consid.to be at incr. risk of prolong. severe neutropen. The safety and efficacy of StimoFil are similar in adults and child. receiv. cytotox. chemother.
Indic. for the mobilisation of peripher. blood progenitor cells (PBPCs).
In pts., child. or adult. with severe congenit., cyclic, or idiopath. neutropen. with an absolute neutrophil count (ANC) of ≤ 0.5 x 109 /L, and a history of severe or recur. infections, long term admin. of StimoFil is indic.to incr. neutrophil counts and to reduce the incidence and durat. of infec.-related events.
Tmt. of persist. neutropen. (ANC less than or equal to 1.0 x 109/L) in pts. with advanced HIV infec., in order to reduce the risk of bacter. infections when other options to manage neutropen. are inappropr.
